Sheehan N J, Slavin B M, Kind P R N, Mathews J A. Increased serum alkaline phosphatase activity in ankylosing spondylitis.
Blood dyscrasia associated with azapropazone therapy SIR, Side effects from effective drugs are inevitable but would be less common if Data Sheet recommendations were invariably followed by prescribers. The letter from Dr Green and his colleagues' illustrates this point. Their patient, who was 80 years old, with reduced renal function was given 1200 mg azapropazone daily, twice the recommended dose. In addition, she had a history of a blood dyscrasia, given in the Data Sheet as a contraindication to the use of this drug.
Azapropazone has been in use in the United Kingdom for nine years and has provided more than two and a half million patient months treatment. To our knowledge there has been no proved case of an adverse effect involving the bone marrow during this time. We trust that Dr Green's letter will draw your readers' attention to the necessity of following Data Sheet recommendations.
A IH Robins Co Ltd. A further reason for an increase in pain and stiffness became apparent in the course of our own trial. If patients begin to feel better, they tend to increase their level of activity, using muscles which may not have been used actively for some time and undertaking heavier work than that to which they had been accustomed. Thus an apparent deterioration in parameters may mask a real improvement in the patient.
Reference is made to a recent trial from New Zealand' which purports to show from an analysis of drop-out rates that Seatone was not superior to placebo in alleviating the symptoms of rheumatoid arthritis. However, in the first six weeks of the trial when all patients were also taking naproxen, 4-3% (one out of 23) of patients on Seatone dropped out of the trial compared with 20-8% (five out of 24) of patients on placebo. At the end of a further six-week period when no patients had naproxen 70% of the Seatone patients and 83% of the placebo patients had dropped out. The numbers were insufficient to make these differences significant, and to avoid a type II statistical error in comparing the two groups at the six-week stage not less than 80 patients would be required in each treatment group. However, any suggested difference is in favour of Seatone.
The tone of the reporting of the Larkin trial could suggest a negative expectation on the part of the investigators. When they referred to our 'attempted controlled trial', they incorrectly described it as having come from the Glasgow Homoeopathic Hospital. In fact the greater part of the preliminary four-year study was carried out at the Centre for Rheumatic Diseases, and the double-blind trial
